SCHEMBL4558943

SCHEMBL4558943

Cc1cccc(-c2csc([C@]3(C)CC(=O)N(CCCN4CCCC4=O)C(=N)N3)c2)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.37
ALDH1A1 P00352 7/20 0.36
NLRP3 Q96P20 1/20 0.35
MEN1 O00255 2/20 0.35
MAPT P10636 2/20 0.34
RAB9A P51151 2/20 0.34
HPGD P15428 2/20 0.34
NPC1 O15118 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.33
IRAK4 Q9NWZ3 1/20 0.33
DRD4 P21917 1/20 0.33
APOBEC3A P31941 1/20 0.33
APOBEC3G Q9HC16 1/20 0.33
BACE1 P56817 1/20 0.33
ADRA1B P35368 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
ADORA1 P30542 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4549184 0.90 BACE1 (0.37) KMT2AALDH1A1MEN1MAPTSMN1; SMN2
SCHEMBL7601282 0.89 BACE1 (0.46) CYP2C9BACE1
SCHEMBL12191301 0.89 BACE1 (0.46) CYP2C9BACE1
SCHEMBL7541964 0.80 BACE1 (0.43) MAPTBACE1L3MBTL1HSD17B10
SCHEMBL4560006 0.78 ROCK1 (0.34) ALDH1A1MAPTHPGDBACE1
SCHEMBL4556924 0.76 BACE1 (0.33) BACE1
SCHEMBL12173515 0.72 REN (0.33) KMT2AALDH1A1MEN1MAPTRAB9A
SCHEMBL12174135 0.72 REN (0.33) KMT2AALDH1A1MEN1MAPTRAB9A
SCHEMBL7542953 0.72 REN (0.33) KMT2AALDH1A1MEN1MAPTRAB9A
SCHEMBL14105642 0.72 BACE1 (0.36) BACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120232064-A1 ASPARTYL PROTEASE INHIBITORS SCHERING CORPORATION (US) 2012-09-13 US disclosed
US-8168641-B2 Aspartyl protease inhibitors SCHERING CORPORATION (US) 2012-05-01 US disclosed
US-20070287692-A1 ASPARTYL PROTEASE INHIBITORS MERCK SHARP & DOHME LLC 2007-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232064-A1 ASPARTYL PROTEASE INHIBITORS CHRM1, CHRM2, BACE1 KMT2A 3239/4885ALDH1A1 3127/4885NLRP3 1489/4885
US-20070287692-A1 ASPARTYL PROTEASE INHIBITORS CHRM1, CHRM2, BACE1 KMT2A 3239/4885ALDH1A1 3127/4885NLRP3 1489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.